Patent application number | Description | Published |
20090158302 | API TRANSLATION FOR NETWORK ACCESS CONTROL (NAC) AGENT - An application programming interface (API) translation agent and method for converting a message from one application configured according to a first API to a message configured according to a second API so that the first application, which is configured to communicate only in accordance with the first API, can communicate with a second application, which is configured to communicate only in accordance with the second API. The first and second applications can include a security application and a network access control (NAC) agent installed on an end point computing device, and the API translation agent can be used by the NAC agent to obtain information regarding a security status of the end point computing device, the information being used to determine whether the end point computing device is in compliance with the security policies of a network. | 06-18-2009 |
20090158407 | API TRANSLATION FOR NETWORK ACCESS CONTROL (NAC) AGENT - An application programming interface (API) translation agent and method for converting a message from one application configured according to a first API to a message configured according to a second API so that the first application, which is configured to communicate only in accordance with the first API, can communicate with a second application, which is configured to communicate only in accordance with the second API. The first and second applications can include a security application and a network access control (NAC) agent installed on an end point computing device, and the API translation agent can be used by the NAC agent to obtain information regarding a security status of the end point computing device, the information being used to determine whether the end point computing device is in compliance with the security policies of a network. | 06-18-2009 |
20090165132 | SYSTEM AND METHOD FOR SECURITY AGENT MONITORING AND PROTECTION - A security agent monitoring and protection system is provided. A security agent on an end point computing device can be accompanied by or can load into the device's memory at startup one or more independent software processes whose primary function is to directly protect the security agent itself and take protective actions against the end point computing device should a security agent protecting the device become disabled. Protection of the security agent can be achieved in several ways, including installing the security agent with restricted permissions, making it difficult to shutdown, restarting the security agent automatically if it is halted without authorization, disabling network connectivity of the end point device if the security agent does not successfully start or restart, protecting executable and dynamic link library (DLL) files of the security agent, and controlling access to the security agent's Common Object Model (COM) interfaces. These protective aspects can also be used by the monitoring agent itself to protect it from unauthorized access or disabling, further providing protection to the device. | 06-25-2009 |
20130254833 | METHODS AND SYSTEMS FOR CONTROLLING ACCESS TO COMPUTING RESOURCES BASED ON KNOWN SECURITY VULNERABILITIES - Methods and systems are provided for fine tuning access control by remote, endpoint systems to host systems. Multiple conditions/states of one or both of the endpoint and host systems are monitored, collected and fed to an analysis engine. Using one or more of many different flexible, adaptable models and algorithms, an analysis engine analyzes the status of the conditions and makes decisions in accordance with pre-established policies and rules regarding the security of the endpoint and host system. Based upon the conditions, the policies, and the analytical results, actions are initiated regarding security and access matters. In one described embodiment of the invention, the monitored conditions include software vulnerabilities. | 09-26-2013 |
Patent application number | Description | Published |
20080311127 | Combination therapy for treating disease - Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen. | 12-18-2008 |
20110091466 | IgE ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA). | 04-21-2011 |
20110256124 | METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE - The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive. | 10-20-2011 |
20130022614 | IgE ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA). | 01-24-2013 |
20130058920 | METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE - The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive. | 03-07-2013 |